Qualified Participants Must:
• Be between 65 and 90 years of age
•
Be experiencing agitation associated with Alzheiemers disease
Qualified Participants May Receive:
Qualified participants will receive:
- Study-related care and treatment with either the study drug or the pacebo for five weeks.
- Compensation for time and travel may be available to patients and caregivers.